Patents by Inventor Shingo Nakatani
Shingo Nakatani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240093052Abstract: Provided is an aqueous coating composition capable of forming a fluororesin coating film layer with excellent electrical properties and surface physical properties, and good adhesive properties. A coating composition containing 2 or more kinds of fluororesins, wherein at least 1 kind of the fluororesin, a fluororesin (I), has a number of functional groups of 30 to 1,000 per 106 main-chain carbon atoms, and the coating composition further contains an inorganic filler, a surfactant, a liquid medium, and a non-fluororesin.Type: ApplicationFiled: November 22, 2023Publication date: March 21, 2024Applicant: DAIKIN INDUSTRIES, LTD.Inventors: Yuki UEDA, Shingo Okuno, Akiyoshi Yamauchi, Yoshihiro Souda, Yasukazu Nakatani
-
Publication number: 20240084158Abstract: Provided is an aqueous coating composition capable of forming a fluororesin coating film layer with excellent electrical properties and surface physical properties, and good adhesive properties. A coating composition containing 2 or more kinds of fluororesins, where at least 1 kind of the fluororesin, a fluororesin (I), has a number of functional groups of 30 to 1,000 per 106 main-chain carbon atoms, and where the coating composition further contains an inorganic filler, a surfactant, and a liquid medium.Type: ApplicationFiled: November 20, 2023Publication date: March 14, 2024Applicant: DAIKIN INDUSTRIES, LTD.Inventors: Yuki UEDA, Shingo OKUNO, Akiyoshi YAMAUCHI, Yoshihiro SOUDA, Yasukazu NAKATANI
-
Patent number: 10717738Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.Type: GrantFiled: July 7, 2017Date of Patent: July 21, 2020Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Steve Courtney, Chris Yarnold, Stuart Flanagan, Gareth Brace, John Barker, Osamu Ichihara, Elise Gadouleau, Anthony Richardson, Takashi Kondo, Akira Imagawa, Shingo Nakatani, Ryo Suzuki, Sho Kouyama
-
Patent number: 9974777Abstract: An object of the present invention is to provide a drug having the inhibitory activity on ENPP2 which is a different target from that of the existing drug, as a medicament useful in a urinary excretion disorder patient for whom the existing drug has the insufficient effect. The present invention provides a compound represented by the general formula (I): (wherein definition of each group is as defined in the description) having the ENPP2 inhibitory activity, a salt thereof or a solvate thereof or a prodrug thereof, and an agent for preventing or treating urinary excretion disorder and/or improving symptoms thereof, containing them as an active ingredient.Type: GrantFiled: March 21, 2017Date of Patent: May 22, 2018Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Akira Ohata, Shingo Nakatani, Tetsuya Sugiyama, Takashi Morimoto
-
Patent number: 9862721Abstract: An object of the present invention is to provide a drug having the inhibitory activity on ENPP2 which is a different target from that of the existing drug, as a medicament useful in a urinary excretion disorder patient for whom the existing drug has the insufficient effect. The present invention provides a compound represented by the general formula (I): (wherein definition of each group is as defined in the description) having the ENPP2 inhibitory activity, a salt thereof or a solvate thereof or a prodrug thereof, and an agent for preventing or treating urinary excretion disorder and/or improving symptoms thereof, containing them as an active ingredient.Type: GrantFiled: October 15, 2015Date of Patent: January 9, 2018Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Akira Ohata, Shingo Nakatani, Tetsuya Sugiyama, Takashi Morimoto
-
Publication number: 20170305917Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.Type: ApplicationFiled: July 7, 2017Publication date: October 26, 2017Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Steve COURTNEY, Chris YARNOLD, Stuart FLANAGAN, Gareth BRACE, John BARKER, Osamu ICHIHARA, Elise GADOULEAU, Anthony RICHARDSON, Takashi KONDO, Akira IMAGAWA, Shingo NAKATANI, Ryo SUZUKI, Sho KOUYAMA
-
Patent number: 9732085Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.Type: GrantFiled: December 20, 2012Date of Patent: August 15, 2017Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Steve Courtney, Chris Yarnold, Stuart Flanagan, Gareth Brace, John Barker, Osamu Ichihara, Elise Gadouleau, Anthony Richardson, Takashi Kondo, Akira Imagawa, Shingo Nakatani, Ryo Suzuki, Sho Kouyama
-
Publication number: 20170189386Abstract: An object of the present invention is to provide a drug having the inhibitory activity on ENPP2 which is a different target from that of the existing drug, as a medicament useful in a urinary excretion disorder patient for whom the existing drug has the insufficient effect. The present invention provides a compound represented by the general formula (1): (wherein definition of each group is as defined in the description) having the ENPP2 inhibitory activity, a salt thereof or a solvate thereof or a prodrug thereof, and an agent for preventing or treating urinary excretion disorder and/or improving symptoms thereof, containing them as an active ingredient.Type: ApplicationFiled: March 21, 2017Publication date: July 6, 2017Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Akira OHATA, Shingo NAKATANI, Tetsuya SUGIYAMA, Takashi MORIMOTO
-
Patent number: 9636330Abstract: An object of the present invention is to provide a drug having the inhibitory activity on ENPP2 which is a different target from that of the existing drug, as a medicament useful in a urinary excretion disorder patient for whom the existing drug has the insufficient effect. The present invention provides a compound represented by the general formula (I): (wherein definition of each group is as defined in the description) having the ENPP2 inhibitory activity, a salt thereof or a solvate thereof or a prodrug thereof, and an agent for preventing or treating urinary excretion disorder and/or improving symptoms thereof, containing them as an active ingredient.Type: GrantFiled: February 25, 2015Date of Patent: May 2, 2017Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Akira Ohata, Shingo Nakatani, Tetsuya Sugiyama, Takashi Morimoto
-
Patent number: 9353113Abstract: An object of the present invention is to provide a drug having the inhibitory activity on ENPP2 which is a different target from that of the existing drug, as a medicament useful in a urinary excretion disorder patient for whom the existing drug has the insufficient effect. The present invention provides a compound represented by the general formula (I): (wherein definition of each group is as defined in the description) having the ENPP2 inhibitory activity, a salt thereof or a solvate thereof or a prodrug thereof, and an agent for preventing or treating urinary excretion disorder and/or improving symptoms thereof, containing them as an active ingredient.Type: GrantFiled: January 5, 2012Date of Patent: May 31, 2016Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Akira Ohata, Shingo Nakatani, Tetsuya Sugiyama, Takashi Morimoto
-
Publication number: 20160031884Abstract: An object of the present invention is to provide a drug having the inhibitory activity on ENPP2 which is a different target from that of the existing drug, as a medicament useful in a urinary excretion disorder patient for whom the existing drug has the insufficient effect. The present invention provides a compound represented by the general formula (I): (wherein definition of each group is as defined in the description) having the ENPP2 inhibitory activity, a salt thereof or a solvate thereof or a prodrug thereof, and an agent for preventing or treating urinary excretion disorder and/or improving symptoms thereof, containing them as an active ingredient.Type: ApplicationFiled: October 15, 2015Publication date: February 4, 2016Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Akira OHATA, Shingo NAKATANI, Tetsuya SUGIYAMA, Takashi MORIMOTO
-
Publication number: 20150231118Abstract: An object of the present invention is to provide a drug having the inhibitory activity on ENPP2 which is a different target from that of the existing drug, as a medicament useful in a urinary excretion disorder patient for whom the existing drug has the insufficient effect. The present invention provides a compound represented by the general formula (I): (wherein definition of each group is as defined in the description) having the ENPP2 inhibitory activity, a salt thereof or a solvate thereof or a prodrug thereof, and an agent for preventing or treating urinary excretion disorder and/or improving symptoms thereof, containing them as an active ingredient.Type: ApplicationFiled: February 25, 2015Publication date: August 20, 2015Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Akira OHATA, Shingo NAKATANI, Tetsuya SUGIYAMA, Takashi MORIMOTO
-
Publication number: 20150152112Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.Type: ApplicationFiled: December 20, 2012Publication date: June 4, 2015Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Steve Courtney, Chris Yarnold, Stuart Flanagan, Gareth Brace, John Barker, Osamu Ichihara, Elise Gadouleau, Anthony Richardson, Takashi Kondo, Akira Imagawa, Shingo Nakatani, Ryo Suzuki, Sho Kouyama
-
Patent number: 9006246Abstract: An object of the present invention is to provide a drug having the inhibitory activity on ENPP2 which is a different target from that of the existing drug, as a medicament useful in a urinary excretion disorder patient for whom the existing drug has the insufficient effect. The present invention provides a compound represented by the general formula (I): (wherein definition of each group is as defined in the description) having the ENPP2 inhibitory activity, a salt thereof or a solvate thereof or a prodrug thereof, and an agent for preventing or treating urinary excretion disorder and/or improving symptoms thereof, containing them as an active ingredient.Type: GrantFiled: July 5, 2011Date of Patent: April 14, 2015Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Akira Ohata, Shingo Nakatani, Tetsuya Sugiyama, Takashi Morimoto
-
Publication number: 20130345426Abstract: An object of the present invention is to provide a drug having the inhibitory activity on ENPP2 which is a different target from that of the existing drug, as a medicament useful in a urinary excretion disorder patient for whom the existing drug has the insufficient effect. The present invention provides a compound represented by the general formula (I): (wherein definition of each group is as defined in the description) having the ENPP2 inhibitory activity, a salt thereof or a solvate thereof or a prodrug thereof, and an agent for preventing or treating urinary excretion disorder and/or improving symptoms thereof, containing them as an active ingredient.Type: ApplicationFiled: January 5, 2012Publication date: December 26, 2013Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Akira Ohata, Shingo Nakatani, Tetsuya Sugiyama, Takashi Morimoto
-
Publication number: 20130109699Abstract: An object of the present invention is to provide a drug having the inhibitory activity on ENPP2 which is a different target from that of the existing drug, as a medicament useful in a urinary excretion disorder patient for whom the existing drug has the insufficient effect. The present invention provides a compound represented by the general formula (I): (wherein definition of each group is as defined in the description) having the ENPP2 inhibitory activity, a salt thereof or a solvate thereof or a prodrug thereof, and an agent for preventing or treating urinary excretion disorder and/or improving symptoms thereof, containing them as an active ingredient.Type: ApplicationFiled: July 5, 2011Publication date: May 2, 2013Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Akira Ohata, Shingo Nakatani, Tetsuya Sugiyama, Takashi Morimoto
-
Patent number: 7968572Abstract: It is intended to provide a compound represented by the formula (I): wherein all the symbols are as defined in the description; which has a p38 MAP kinase inhibitory activity, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. The compound of the invention is useful for preventing or treating a disease in which the abnormal production of a cytokine such as an inflammatory cytokine or a chemokine or overreaction to them is considered to be involved in the cause and aggravation of pathological conditions, in other words, an inflammatory disease, a respiratory disease, a cardiovascular disease, a central nervous system disease or the like, which is a cytokine-mediated disease.Type: GrantFiled: October 2, 2006Date of Patent: June 28, 2011Assignee: Ono Pharmaceuticals Co., Ltd.Inventors: Hisao Nakai, Shingo Yamamoto, Shingo Nakatani, Tomomi Hirosaki
-
Patent number: 7713998Abstract: The present invention relates to a compound that has p38 MAP kinase inhibitory activity useful as drug medicine, represented by the general formula (I): wherein all the symbols are as defined in the description, or its salt, N-oxide or solvate, or a prodrug thereof. Further, there are provided a process for producing the same and usage thereof. The compound of the general formula (I) has a p38 MAP kinase inhibitory activity and is useful for the prevention and/or treatment of diseases in which an abnormal production of cytokine, such as inflammatory cytokine or chemokine, or an over-reaction thereto would be instrumental in the cause and aggravation of pathologic condition thereof, namely, cytokine-mediated diseases, for example, inflammatory diseases, respiratory diseases, circulatory diseases, central nervous diseases, etc.Type: GrantFiled: November 9, 2005Date of Patent: May 11, 2010Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Hisao Nakai, Shingo Yamamoto, Shingo Nakatani, Tomomi Hirosaki
-
Publication number: 20100063104Abstract: It is intended to provide a compound represented by the formula (I): wherein all the symbols are as defined in the description; which has a p38 MAP kinase inhibitory activity, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. The compound of the invention is useful for preventing or treating a disease in which the abnormal production of a cytokine such as an inflammatory cytokine or a chemokine or overreaction to them is considered to be involved in the cause and aggravation of pathological conditions, in other words, an inflammatory disease, a respiratory disease, a cardiovascular disease, a central nervous system disease or the like, which is a cytokine-mediated disease.Type: ApplicationFiled: October 2, 2006Publication date: March 11, 2010Applicant: ONO PHARMACEUTICAL CO., LTD.,Inventors: Hisao NAKAI, Shingo YAMAMOTO, Shingo NAKATANI, Tomomi HIROSAKI
-
Publication number: 20070265308Abstract: The present invention relates to a compound that has p38 MAP kinase inhibitory activity useful as drug medicine, represented by the general formula (I): wherein all the symbols are as defined in the description, or its salt, N-oxide or solvate, or a prodrug thereof. Further, there are provided a process for producing the same and usage thereof. The compound of the general formula (I) has a p38 MAP kinase inhibitory activity and is useful for the prevention and/or treatment of diseases in which an abnormal production of cytokine, such as inflammatory cytokine or chemokine, or an over-reaction thereto would be instrumental in the cause and aggravation of pathologic condition thereof, namely, cytokine-mediated diseases, for example, inflammatory diseases, respiratory diseases, circulatory diseases, central nervous diseases, etc.Type: ApplicationFiled: November 9, 2005Publication date: November 15, 2007Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Hisao Nakai, Shingo Yamamoto, Shingo Nakatani, Tomomi Hirosaki